

References

- a DelveInsight. *Allegra's Cefepime/enmetazobactam market size expected to increase many folds by 2032*, Report DelveInsight. 2024. Available from: <https://www.barchart.com/story/news/23915599/allecras-cefepimeenmetazobactam-market-size-expected-to-increase-many-folds-by-2032-report-delveinsight>, accessed on July 22, 2025.
- b Hospital Healthcare Europe. *New antibiotic cefepime/enmetazobactam receives positive CHMP opinion for cUTIs.* Available from: <https://hospitalhealthcare.com/clinical/new-antibiotic-cefepime-enmetazobactam-receives-positive-chmp-opinion-for-complicated-urinary-tract-infections/>, accessed on July 22, 2025.
- c Bonnin RA, Jeannot K, Santerre Henriksen A, Quevedo J, Dortet L. *In vitro* activity of cefepime-enmetazobactam on carbapenem-resistant Gram negatives. *ClinMicrobiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis Clin Microbiol Infect.* 2025;31:240–9.
- d Bakthavatchalam YD, Shankar A, Abdullah F, Srinivasan D, Ragothaman H, KrishnaMoorthy S, *et al.* In-vitro activity of cefepime/enmetazobactam against extended spectrum beta-lactamases and/or ampC producing Enterobacterales and *Pseudomonas aeruginosa* collected across India. *Diagn Microbiol Infect Dis.* 2025;113:116993.
- e Kauvery Hospital. *Evaluation of cefepime-enmetazobactam against ESBL and AmpC β -lactamase producing Gram-negative bacteria: In vitro study - Kauvery Hospital.* 2025. Available from: <https://www.kauveryhospital.com/kauverian-scientific-journal/evaluation-of-cefepime-enmetazobactam-against-esbl-and-ampc/>, accessed on July 27, 2025.